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A B S T R A C T
The 2014–2016 Ebola epidemic presented a challenging setting in which to carry out clinical trials. This paper
reports ﬁndings from social science research carried out in Kambia, Northern Sierra Leone during ﬁrst year of an
Ebola vaccine trial (August 2015–July 2016). The social science team collected data through ethnographic
observation, 42 in depth interviews; 4 life narratives; 200 exit interviews; 31 key informant interviews; and 8
focus group discussions with trial participants and community members not enrolled in the trial. Whilst research
often focuses on why people refuse vaccination, we instead explore participant motivations for volunteering for
the study, in spite of prevailing anxieties, rumours and mistrust during and after the Ebola outbreak. In so doing
the paper contributes to on-going debates about research ethics and community engagement in resource poor
contexts, oﬀering reﬂections from an emergency and post-epidemic setting. We analyse participants' perceptions
of the risks and beneﬁts of participations, highlighting the importance of a contextual approach. We focus on
four types of motivation: altruism; curiosity and hope; health-seeking; and notions of exchange, and argue for the
role of social science in developing grounded research ethics and community engagement strategies that can take
into account context and local realities.
1. Introduction
The 2014–2016 Ebola epidemic in Guinea, Liberia and Sierra Leone
was the largest in history, with over 14000 cases and approximately
4000 deaths in Sierra Leone alone (Centers for Disease Control and
Prevention (CDC), 2016). At the time of the outbreak, there was no
licensed vaccine or treatment available for Ebola, leading to the rapid
establishment of clinical trials of experimental products. The time
pressure under which researchers had to work was complicated further
by limited research experience in the aﬀected countries, and a pro-
tracted history of structural violence having eroded trust in both na-
tional and international organisations across the region (Wilkinson and
Leach, 2015).
As the disease spread, reports were rife of community resistance to
medical intervention, mistrust of healthcare facilities, and stigmatisa-
tion of health workers and survivors (Chandler et al., 2015; Fairhead
et al., 2006). Rumours spread about the potential origins of the disease,
including political conspiracies and international blood-stealing cartels
(Bolten and Shepler, 2017; ICG, 2015; Leach, 2015). In a time of un-
certainty, the establishment of clinical trials for experimental treat-
ments and vaccines raised signiﬁcant challenges for researchers and
community engagement teams.
In this paper, we report ﬁndings from anthropological research
carried out during an Ebola vaccine trial, EBOVAC-Salone, based in
Kambia, Sierra Leone. This trial, funded by the Innovative Medicines
Initiative, is evaluating the safety and immunogenicity of the
Ad26.ZEBOV/MVA-BN-Filo prime-boost Ebola vaccine regimen in an
aﬀected population. Enrolment of healthy adults into a small, open-
label initial stage of the study took place in October 2015. In March
2016, enrolment began into a randomised, controlled study stage,
which ﬁrst recruited adults before recruiting adolescents and lastly
children aged 1 year and older. The discussion in this paper is based on
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research carried out in Kambia between August 2015, as the trial was
being set up and as the epidemic was on-going but reaching its ﬁnal
stage, and July 2016, as the second stage of the trial had begun for adult
participants and four months after the last oﬃcial declaration of the
end of the epidemic. Through ethnographic methods, interviews and
life narratives, we explored the subjective experiences of participants in
the early stages of this trial. We asked why, in an environment of fear,
rumours and mistrust, Kambians volunteered to take part in the trial.
The aim of this paper, therefore, is to analyse participant motivations
for volunteering for an Ebola vaccine study, and to consider the im-
plications of such motivations for clinical research ethics and commu-
nity engagement in trials in low-resource settings.
Although research on motivations for healthy participants to vo-
lunteer in clinical trials has been limited, particularly in developing
countries (Stunkel and Grady, 2011), there is a growing body of work
on community engagement and research ethics in resource poor set-
tings (Leach et al., 1999; Molyneux and Bull, 2013; Molyneux and
Geissler, 2008). This literature has pointed to the complexity of context-
speciﬁc social and economic factors that shape the experience of par-
ticipants in clinical research and therefore the practical implications for
seeking consent against this backdrop. In particular, a number of stu-
dies have pointed to the “subjective experiences of social and economic
constraints on voluntariness” and the ways in which “inequalities and
social power permeate all community engagement and consent activ-
ities” (Molyneux and Bull, 2013, p. 5; 10). There is also some evidence
around decision-making in clinical research, including for example a
number of studies that show the importance of access to healthcare in
mothers' decisions to enrol their children in clinical studies in countries
with limited service availability (Mtunthama et al., 2008; Nabulsi et al.,
2011). We hope to contribute to this burgeoning literature by oﬀering
reﬂections from the context of an epidemic and emergency outbreak
response.
Decision-making lies at the foundations of research ethics and how
we think about informed consent. The essence of research ethics stan-
dards since their inception has been the notion that people should “not
only decide freely whether to participate in clinical research, but decide
with an understanding of the relevant facts” (Flory et al., 2008, p. 645).
On-going debates in bioethics also address the basis of decision-making
in terms of the implications of the potential “misconceptions” or
“misestimations” of clinical study participants (Horng and Grady, 2010;
Kimmelman, 2007). Similarly, strong disagreements about whether
participation in medical research ought to be remunerated or even
considered as a form of labour—most starkly represented in the title of
Dickert and Grady's (1999) provocative paper, What's the Price of a
Research Subject?— reﬂect a preoccupation with the ethical implica-
tions of the motivations for taking part in clinical studies. These ques-
tions underpin the broader concern with how we deﬁne the social value
of research and how this can be determined empirically (Rid and Shah,
2017).
Existing literature on immunisation programmes and risk commu-
nication also oﬀers a useful framework for thinking through motiva-
tions. This body of work has focused in particular on the determinants
of “vaccine hesitancy” along three domains: conﬁdence (trust in the
product and the provider), complacency (perception of need for the
vaccine) and convenience (access) (Larson, 2013). Recent attempts to
measure hesitancy to take vaccines across contexts have shown that
conﬁdence is the primary factor (Larson et al., 2015). In particular,
intentions to take vaccines, especially newly introduced ones, have
been found to correlate with trust in the broader healthcare system
(Larson et al., 2015; Marlow et al., 2007; Ozawa and Stack, 2013). An
emphasis on conﬁdence in the context of vaccination campaigns high-
lights the need to engage with the concept of risk.
Over the years, scholars have increasingly asked for risk commu-
nication to take into account the social construction of risk (Larson
et al., 2012; Slovic, 1994; Hobson-West, 2003; Abraham, 2009; Beck,
1992). This means ﬁrstly considering how diﬀerent systems of
knowledge, and varying levels of trust in the sources of information
provided, inﬂuence individual assessments (Hobson-West, 2003). In
addition, it entails an appreciation of how risk is publicly perceived.
Slovic (1994), for example points to a crucial mismatch between expert
assessments of risk (measured for example by expected fatalities) and
public perceptions of “riskiness” which rely on a much richer combi-
nation of assessments, including familiarity with the type of accident,
the threat posed to future generations and so on. A train wreck that
could kill hundreds of people may be perceived as less of a risk than
terrorist attacks with far fewer victims. Similarly, Beck (1992) sug-
gested that perceptions of how risk is distributed across society matters
for how messaging around risk is received. These insights show that
social, cultural and political dimensions of risk perception must be
central to how we understand public attitudes to health interventions.
When transposed to the context of clinical studies during a complex
emergency such as that produced by the Ebola epidemic in West Africa,
these issues take on particular salience and raise questions for the ethics
of medical research during outbreaks. Understanding why participants
in the EBOVAC-Salone trial decided to put themselves forward to take
an experimental vaccine during a time of uncertainty, despite sig-
niﬁcant ambivalence towards external intervention, and in a region
with limited experience of medical research, thus presents an oppor-
tunity to revisit these questions in an empirically grounded manner. In
so doing we build on existing literature on research ethics in resource
poor settings to consider how experiences with an unprecedented
emergency in West Africa can contribute to growing calls for ethical
approaches that can take social, political and economic contexts ser-
iously.
Whilst it may seem obvious why people would opt to take part in a
study of a vaccine to protect from Ebola in the immediate aftermath of a
deadly epidemic, we show that in fact the value of research and vac-
cination in a context of high levels of mistrust was socially contested.
Indeed, as we have previously shown (Enria et al., 2016), the value of
qualitative research alongside a clinical trial can help show how con-
textual factors shape perceptions of and attitudes towards biomedical
interventions, including perceptions of risk that may be counter to
those of clinical risk assessments. Taking subjective assessments ser-
iously then, not only helps us understand possible tensions between
clinical and social ethics but also to see what determines participation
in a vaccine trial where vaccine hesitancy is prevalent. Our aim is not to
assess the quality of informed consent on the EBOVAC-Salone trial on
its own terms. Instead, we hope to show how, by taking into account
individual participants' reﬂections on their motivations for joining a
clinical trial in a post-epidemic setting, we can contribute to the de-
velopment of a “grounded ethics” framework cognizant of local reali-
ties, and to suggest what the implications might be for community
engagement for clinical research in developing countries.
Our approach stems from the anthropology of medical research,
which explores social critiques and understanding of “postcolonial
techno-science” (Fairhead et al., 2006). Through the lens of social
narratives about science, anthropologists of clinical trials have shown
the diﬀerent “cultural worlds and material concerns” of researchers and
communities hosting research (Fairhead et al., 2006). Applying this lens
to the Ebola crisis and its aftermath, we show how EBOVAC-Salone
participants' articulations of their motivations to join the trial were
framed around socially shared and collectively negotiated meanings
that were often external to the clinic.
After a methodological discussion, we explore the signiﬁcance of
rumours and mistrust in Kambia during and after the Ebola epidemic.
This contextualizes participants' decision-making and lays the founda-
tions for an analysis of how their perceptions of risk were shaped by
history and social engagements with the epidemic. We then outline the
four main motivations reported by vaccine trial participants: altruism;
curiosity and hope; health seeking; and exchange. The paper concludes
with reﬂections on how examining participants' decision making pre-
sents opportunities and challenges for research ethics grounded in
A.F. Tengbeh et al. Social Science & Medicine 203 (2018) 35–42
36
everyday realities and social worlds (grounded ethics) in resource-poor
settings and for the increasingly central role of community engagement
in clinical trials.
2. Methods
The EBOVAC-Salone study was funded by the Innovative Medicines
Initiative's Ebola + programme in December 2014. The study is co-
ordinated by the London School of Hygiene &Tropical Medicine
(LSHTM), in collaboration with the College of Medicine and Allied
Health Sciences (COMAHS) in Sierra Leone, and is sponsored by
Janssen, who have developed the protocol and provided ﬁnancial and
in-kind support (e.g. cost of development, manufacture and shipping
vaccines, cost of trial monitoring, funding to an international NGO to
provide logistic oversight).
This paper is based on research carried out by the research team
between August 2015 and July 2016, encompassing the trial's set up
phase, and the ﬁrst months of vaccination. This overlapped with the
end of the outbreak, which was initially declared over in November
2015 and then again in March 2016 after a ﬂare-up. The role of the
social science team was to produce academic research on the accept-
ability of the vaccine trial; and to work in conjunction with a com-
munity engagement team to develop community-led approaches to
participant recruitment. The community engagement team led on
community and household-level meetings, in conjunction with com-
munity leaders, to explain the conditions for participation and partici-
pants underwent an informed consent process at the clinic (see Enria
et al., 2016; Mooney et al., in preparation).
Within EBOVAC-Salone the social science team contended with the
tension between ensuring independence and providing critique whilst
also generating impactful ﬁndings that can support the intervention.
Whilst committed to supporting the running of the trial in a way that
was responsive to socio-cultural context and participant experience, the
team also put in place measures to maintain academic independence.
One of these, for example, was the separation of social science and
community engagement within the trial team, so that ethnographic
observation was not coupled with volunteer recruitment drives.
Similarly, systems were put in place to ensure the conﬁdentiality of all
data collected also within the team, so that anonymity was maintained
for example when reporting rumours to be addressed by the community
engagement team.
The social science component of the research project used qualita-
tive research methods to explore community and participant percep-
tions and experiences of the trial. The methods included: ethnographic
observation in Kambia's social grounds like attaya bases (tea shops),
market places, local bars and other social gathering places, as well as in
the vaccine clinics, to learn about participant experiences during clinic
visits; exit interviews (200) conducted at the trial clinics with study
participants immediately after visits; in-depth interviews (42) and life
narratives (4) with participants. We also conducted focus group dis-
cussions with both trial participants (4) and community members (4)
and key informant interviews (31) to explore community and partici-
pant perceptions and experiences of the EBOVAC-Salone trial.
Interviews and discussions were carried out in Krio or Temne. The team
used these qualitative research methods to explore the socio-cultural
context and perceptions of illness, disease and medical interventions in
Kambia. The data collected were transcribed and analysed using NVIVO
11. Ethical approval for this study was granted by the London School of
Hygiene & Tropical Medicine Ethics Committee and by the Sierra Leone
Ethics and Scientiﬁc Review Committee. Interviews were anonymysed
and names used in this paper are pseudonyms.
3. Findings
3.1. Rumours, mistrust and perceptions of risk
As the trial was being set up, Kambia was one of the last districts
still recording new cases of Ebola in the country. A military deploy-
ment, Operation Northern Push, was under way to enforce state of
emergency regulations to isolate the last cases. In order to understand
the environment in which participants decided to join the EBOVAC-
Salone trial, we consider widespread mistrust and rumours circulating
about the vaccine during and after the outbreak. These narratives give a
glimpse into the social meaning invested in science and the cultural and
historical speciﬁcity of conducting a vaccine trial in the wake of a
public health emergency. Further, prevailing anxieties surrounding the
trial in Kambia highlight that the value (at the social, community and
individual level) of research is contested and constantly negotiated.
Because of widespread ambivalence towards biomedical interventions
within communities during the outbreak, studying social perceptions of
the trial and asking participants why they decided to join despite con-
cerns surrounding the study oﬀered an invaluable window into the
complex questions around research ethics and engagement during
emergencies.
During the outbreak, responders in West Africa identiﬁed mistrust
as a major challenge, with resistance to interventions seen as a result of
popular misunderstandings (Chandler et al., 2015). Anthropologists and
community activists emphasised instead the social signiﬁcance of ru-
mours, understanding mistrust as emerging from histories of exploita-
tion and extraction as well as contemporary realities (Richards, 2016).
Rumours can accordingly be more productively seen as “modern com-
mentaries” (Geissler and Pool, 2006, p.975) and, as recognised by
historians of medical research in Africa, can reﬂect “meandering epis-
temologies many Africans used to describe the extractions and inva-
sions in which they [live]” (White, 2000, p.5). Rumours then, are not
simple misunderstandings but can convey “more generalised concerns
about medical interventions” (Enria et al., 2016, p. 8). The narratives
surrounding the EBOVAC-Salone trial outlined below are windows into
people's social and political realities, ranging from mistrust of a di-
lapidated national healthcare system to ambivalence regarding the role
of international actors in Sierra Leone's aﬀairs. Contextualising mistrust
as well as hopes, dreams and expectations sets the stage for under-
standing how some people overcame fears, developed counter narra-
tives, and decided to take the Ebola vaccine candidate as the new clinic
opened in Kambia town in September 2015.
3.2. Mistrust of the healthcare sector during the Ebola outbreak
Mistrust of clinical research in Kambia has deep roots in the history
of failed promises from the Sierra Leonean healthcare sector. As many
commentators have noted, the Ebola epidemic tragically exposed the
shortcomings of healthcare facilities in the three aﬀected countries
(Dubois et al., 2015; MSF, 2015). The health care system in Sierra
Leone was undoubtedly overwhelmed by the sheer magnitude of the
outbreak, but the inability of the state to deliver health services had
been apparent well before Ebola. Health outcomes amongst the worlds'
worst (WHO, 2017) have been attributed to poor resource management,
corruption and years of chronic under-spending on health and social
care services (Benton and Dionne, 2015; Conteh, 2016; Pieterse and
Lodge, 2015; Stubbs et al., 2016). Against this backdrop, average Sierra
Leoneans' experiences of healthcare, especially outside urban centres,
tend to be characterised by long journeys, “Kafka-esque bureaucracies”
and disappointing care, explaining widespread avoidance of health
centres (Ferme, 2014). Indeed, in our ethnographic research in Kambia
during and after the epidemic, perceptions of a lack of professionalism
among healthcare workers and previous experiences of inadequate care
were cited as key reasons for avoiding health centres even before the
epidemic. Such mistrust was heightened during the epidemic by fears of
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contracting Ebola in government hospitals and specialist treatment
centres.
Healthcare workers were also implicated in popular theories
claiming that Ebola was not “real” but a ploy by the government and/or
the international community to reduce the West African population
(Wilkinson and Leach, 2015; Bolten and Shepler, 2017; Enria et al.,
2016; Shepler, 2017). The instruments of medical personnel came to
symbolise these theories, for example as rumours circulated in Kambia
about the use of chlorine to suﬀocate patients in ambulances and
treatment centres. These rumours reﬂected deep-seated misgivings
about national healthcare facilities and staﬀ, as well as distrust in
Western involvement. Outsiders were portrayed in popular discourse as
potential saviours or as having ulterior motives. Rumours about people
being murdered and having their blood taken in Ebola treatment cen-
tres mirrored those recounted by anthropologists and historians of co-
lonial medicine across Africa (White, 2000). Such narratives, centred on
mysterious extractions, have been related to histories of slavery, colo-
nialism and the post-independence power of global capital (Comaroﬀ
and Comaroﬀ, 1999). The stories about theft of blood and organs in
Ebola treatment centres were thus part of a longer history of com-
mentaries on inequality and expropriation, envisioned as drainage of
life from Africa to the West.
The epidemic, in other words, did not generate, but exacerbated a
profound sense of mistrust of healthcare facilities, health professionals
and Western intervention. This is especially signiﬁcant if we consider
the evidence on vaccine hesitancy which points to linkages between
trust in the healthcare providers and perceptions of immunisation
drives (Larson, 2013; Larson et al., 2015; Marlow et al., 2007). The trust
deﬁcit evident during the outbreak created a diﬃcult landscape for
clinical researchers hoping to recruit individuals to come to a Western-
funded clinic, to donate their blood for testing the safety and im-
munogenicity of an Ebola vaccine candidate. However, participants'
motivations for joining the vaccine trial help us move beyond a single
story of mistrust to see how people overcame fears and how they made
sense of their decisions in the context of the outbreak.
3.3. Rumours about EBOVAC-Salone
In the context of the broader lack of conﬁdence in the healthcare
system, alongside anxieties about the interventions imposed in the
Ebola response, it is no surprise that as the EBOVAC-Salone trial opened
its doors in September 2015, several rumours circulated about what the
new clinic and its staﬀ might be doing. Many of the rumours were
Sierra Leonean variations of social commentaries collected across re-
search sites in diﬀerent countries (Geissler and Pool, 2006).
One common rumour was that the vaccine was a form of “slow
poison” that might give participants Ebola or another unknown disease:
Some were saying that we don't know the white men; that they can
give slow poison to people for one month, two months, three months
and nothing will happen to the person. And when it is ready to work
in your system it will just happen (Male Participant 27.10.2015)
This rumour played on the widespread confusion about the origins
of Ebola in West Africa and the fact that the arrival of the disease in the
region had seemingly caught everyone oﬀ-guard. Kambians' concerns
about the possibility of the future negative eﬀects of the vaccine re-
vealed anxieties among participants and community members that
another outbreak might occur, rooted in broader uncertainty about the
future of health security in the region.
The trial's requirement that participants give blood between eight
and ten times similarly meant that the fears about blood stealing that
emerged during the outbreak were easily transferred to the vaccine
trial. For some, the rumour of a Western blood bank that needed re-
plenishing to keep Europeans young through the blood of young
Africans seemed to be conﬁrmed by the trial's shipping of samples
abroad. This was especially meaningful given the much discussed
discovery of containers of blood found at Sierra Leone's international
Airport during the epidemic (Patasie, 2015; Thomas, 2015). A Kambian
elder spoke of the aﬀair in relation to the vaccine:
[They] are telling lies that [the vaccine] is Ebola, [it is here] to
capture people, draw their blood, put it into a container and take it
out. You see? They said they saw a lot of containers full of blood at
the Airport, so that caused more fear. They said: ‘The white men
need blood at their Bank, there is no blood there!’ (Key Informant
25.09.2015)
Blood-stealing rumours tend to be explained as metaphors of the
occult, yet this can obscure the speciﬁc signiﬁcance of blood in people's
understanding of health and wellbeing (Fairhead et al., 2006). Parti-
cipants and non-participants alike reported rumours about blood and
related them to a general discomfort around giving blood and a feeling
that it would leave people permanently weakened. The amount of blood
in the body was associated with wellbeing, with illnesses such as ma-
laria deﬁned as being “short in blood”. Having enough and “good”
blood was similarly associated with good health and self-care as a
prospective participant explained:
It took me years to make this blood; I never drank alcohol, nor
smoked marijuana, so I expect the trial to [compensate us] for the
sacriﬁces we are making” (Male Participant 9.10.2015)
In addition to reluctance around the requisite blood taking (and
later also around contraception), tensions emerged around the “in-
centives” oﬀered for taking part in the trial. The EBOVAC-Salone trial
oﬀered participants compensation for transportation to get to the clinic.
However, other trials taking place at other locations in the country at
the same time, generally oﬀered participants more money and some-
times a mobile phone. Discussions thus emerged around compensation,
and some saw the provision of incentives as a worrying commodiﬁca-
tion that was tantamount to exchanging blood, one's life essence, for
money. The notion that participants were “selling their lives” occa-
sionally resulted in derision of those considering participation in the
trial.
Memuna, a female teacher who decided to join the trial with a
neighbour, described their experience as they walked to the clinic:
People made us afraid. […] So on our way [to the clinic] they made
remarks to us, saying: ‘Ah, two dead bodies are on their way’. I said:
‘God will protect us, that is what we pray every day, God will save
us, let's go’. So we came. (Female Participant 5.04.2016)
Rumours need not be barriers to participation (Geissler and Pool,
2006) and indeed EBOVAC-Salone did not face signiﬁcant problems in
recruiting participants for the trial during the ﬁrst stage of the study
(see Enria et al., 2016). Yet Memuna's words, echoed by other partici-
pants, show how rumours, anxieties and mistrust surrounding the trial
inﬂuenced participants' experiences as they decided to join. The fact
that the study was taking place in the wake of a deadly epidemic and a
militarised state of emergency cannot be ignored. Indeed, while parti-
cipants did not necessarily believe the rumours, and often dismissed
and ridiculed them, their subjective assessments were nevertheless
shaped by the context of the crisis. We describe below how, in Kambia,
rumours and anxieties were more than commentary: they informed how
participants understood the risks they were taking, irrespective of the
assessments presented to them by researchers.
4. Reasons for taking part in the EBOVAC-Salone vaccine trial
As rumours and apprehensions circulated, we explored participants'
motivations to join the new vaccine trial in Kambia. We found that in
participants' reﬂections on their decision-making processes, four main
themes emerged: altruism; curiosity; health seeking and beliefs about
the vaccine's powers; and expectations and notions of exchange.
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4.1. Altruism
Several participants framed their participation through notions of
‘sacriﬁce’. This must be understood ﬁrst through an appreciation of the
level of risk that participants felt they were taking when agreeing to
enter the study. Several participants suggested that they thought there
was a high probability that they might become seriously ill or die as a
result of the vaccination. Mammy Isatu, an older female participant,
recounted vividly in a focus group discussion the fear that she felt be-
fore taking the vaccine:
I held my body and prayed all the suras [verses of the Qu'ran] that I
know, as the nurses prepared their papers, I said the kalima
[Qu'ranic recitation] as they injected me (Female Participants Focus
Group 12.05.2016)
In the face of such perceived risk, some participants talked about the
feeling that taking part in the trial was their duty as a citizen, especially
in the aftermath of Ebola and the devastation that the epidemic had
brought to their communities. The notion of sacriﬁce, used by several
participants, was emblematic of this convergence of altruism with a
perception of high risks associated with the study (see also Enria & Lees
in preparation). As one participant put it:
We are real heroes in this country […] we are ready to die for this
country”. (Male Participant 22.10.2015)
The language of “heroism”, used also to refer to those ﬁghting Ebola
as part of the response, was applied here to a sense that taking the
vaccine in order to prove whether it would protect people from the
virus was an act of altruism, a sacriﬁce with potentially deadly con-
sequences.
The language of sacriﬁce was used especially by those who saw
themselves, and were recognised by others, as leaders in the commu-
nity, such as pastors and imams, traditional heads, and other respected
personalities. Their descriptions of their own motivations emerged from
a sense of responsibility to the community that they represented, as
summarised by one Pastor:
As their spiritual father, I have come to build their conﬁdence, if
nothing happens to me, my congregation will join. (Male Participant
8.10.2015)
The idea that leaders should be the ﬁrst to “sacriﬁce” for their
communities was supported by assertions recorded throughout our
ethnographic ﬁeldwork that if community leaders put themselves for-
ward for this study and came out unscathed, others would join.
Sacriﬁce for others was described a key reason for taking part, espe-
cially amongst those who joined the ﬁrst stage of the trial. The ex-
pectations placed on community leaders must be understood in the
context of local moral economies, whereby personal power is expected
to be balanced by material support and responsibility for those who
made ascent to power possible (Bolten, 2012; Enria, 2018). Further-
more, self-reporting morally virtuous motivations also points to the
challenge of engaging with subjective descriptions, and highlights im-
portance of considering a multiplicity of determining factors.
4.2. Curiosity and hope
Notions of risk and sacriﬁce rest on particular understandings of and
responses to uncertainty. Prevailing views about uncertainty, focused
solely on vulnerability and precariousness, conceal the many ways in
which uncertainty can be experienced as productive and as holding the
potential for a better life (Cooper and Pratten, 2015). In a focus group
with female participants on the notion of risk, the fear associated with
taking a risk was counterbalanced by a sense of opportunity, the pos-
sibility that one might succeed. “Eagerness to know” was cited as one of
the reasons why one might take a risk with uncertain outcomes. Indeed,
when talking with study participants speciﬁcally about their decision to
take a vaccine with uncertain consequences, some emphasised an ele-
ment of curiosity and a wish to explore something new and potentially
dangerous. One respondent noted for example that his intention in
coming to the clinic had been to test the rumours he had been hearing
and to dispel his own anxieties:
I was afraid, so I decided to come and do research to see if this
medicine is here to kill people as other people are saying. (Male
Participant 12.04.2016)
Importantly, participants explained their personal strategies for
dealing with risk in the trial by placing their decisions in the broader
context of lives characterised by uncertainty:
Even the food that you eat is a sacriﬁce because you can eat it and
anything can happen. (Male Participant 8.12.2015)
In this shifting, unpredictable landscape, many participants sought
certainty in religion and explained their participation through faith in a
higher power:
Die nar wan tem [You only die once], only God can mark your death.
(Female Participants Focus Group 12.05.2016)
Although this might be interpreted as a form of fatalism or aban-
donment of agency, many respondents linked their faith purposively to
their actions in life: “You should be ready to think positive, then God
will do you good, if you sit and think bad, that is what God will give
you” (Female Participants Focus Group 12.05.2016). This notion that
good actions and intentions are rewarded by God, helped many parti-
cipants overcome fear and see the risk they felt to be taking within the
study as a potential opportunity. Others pinned their hope on a tenta-
tive expression of trust in “foreigners” or the government as gate-
keepers of research, showing a more complex story about mistrust,
whereby those who decided to join the study overcame fears and placed
trust in the intervention despite high levels of perceived risk (see also
Enria & Lees in preparation).
4.3. Health-seeking and beliefs about vaccine's powers
The trial as an opportunity took diﬀerent guises for diﬀerent par-
ticipants. Attitudes to vaccination include an assessment of the per-
ceived likelihood that the vaccine will be necessary (Larson et al.,
2015). For EBOVAC-Salone participants the ﬁrst perceived opportunity,
which made joining the study worth taking a risk, was the potential
protection from a future outbreak:
[The Ebola vaccine] is very important looking at the disaster it has
caused in the sub-region and our country in particular. With its
presence in our bodies, it will stop the deaths, and [Ebola] will not
disturb the economy again. (Male Participant 12.10.2015)
On some occasions this was expressed in terms of a hopeful con-
viction that the vaccine would be protective, as some participants felt
that having not experienced any side eﬀects proved the vaccine to be
safe:
They said [that] when an Ebola outbreak happens in a country
maybe in one or two or three years it will come back, and when it
comes back it will be more dangerous. But when you complete
taking the marklate you are free from [Ebola]. So that gave me more
[conﬁdence] that now that we have taken the ﬁrst one and nothing
happened to us. (Male Participant 17.12.2015)
It was more common, especially after the epidemic was declared
oﬃcially over, to ﬁnd participants' motivations to be rooted in a more
generalised belief that the trial and the vaccine itself symbolised an
ideal of good health and that participating therefore meant taking care
of one's health.
In post-vaccination interviews, participants portrayed the trial as
“ﬁghting for [their] health”, and argued that they would recommend
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that their families and friends join because: “it is a health seeking
process, it's good that we play an active part in it” (Male Participant
19.10.2015). This must be understood in conjunction with the negative
perception of government-provided healthcare noted above, in contrast
to the trial's provision of a higher standard of care. The health-checks
that participants had to undergo to determine their eligibility for the
study were often perceived to be of higher value than the vaccine itself,
given that the majority of Kambians entering the trial had never had a
medical check-up before. “Knowing one's status” was thus frequently
cited as a perceived beneﬁt of participation:
What I enjoyed more, was the screening that I underwent with the
doctor. They asked me a lot of question about my health, [and …]
they told me that I am really healthy and up to this time I am feeling
healthiness in my body. (Male Participant 8.12.2015)
The provision of free healthcare for non-chronic conditions for those
involved in the trial was similarly a signiﬁcant motivation for Kambians
to join. As one young man told us in an interview, he had been suﬀering
from recurrent headaches and stomach aches and was hopeful that the
trial team might be able to help him address these problems:
“[The trial] is good, it is free to us and also what made me become
more interested [was that] if I have a head ache, after taking the
injection, I can just inform them that my head is aching, so I thought
that this will just make me get my health […] These are the major
things that made me join the trial. So I think I will get help from this
people. (Male Participant 2.04.2016)
Participants' mention of access to higher standards of care as an
incentive for joining is consistent with existing anthropological litera-
ture on participation, including in the MRC trials in The Gambia
(Fairhead et al., 2006; Leach and Fairhead, 2008). This of course raises
important questions around the social justice implications of a clinical
study that provides healthcare to participants that are selected on the
basis of their good health through a screening process. Participants who
failed screening were treated for short-term conditions such as malaria
or referred to the appropriate healthcare facility. EBOVAC-Salone also
provided support to the Kambia government hospital, including re-
furbishing the paediatric ward. Nonetheless, as we discuss below, the
role of healthcare provision in participants' motivations has important
implications for how we think about ethics across contexts.
The conviction that the trial was associated with “good health” also
went beyond the concrete ways in which the trial provided free
healthcare. Some participants also reported having experienced special
healing powers from the vaccine:
To me the vaccine does not only prevent Ebola, it also prevents some
minor illnesses like rash etc. I have experienced it! (Male Participant
21.10.2015)
One participant reported that the ﬁrst dose of the vaccine had led to
his hernia disappearing:
When I used to cough, this place got swollen and I used to squeeze it,
it was like a lump, so I asked and somebody told me that it was
hernia, from the time after taking the ﬁrst [vaccine] I noticed that it
disappeared and there is no more pain like that (Male Participant
27.10.2015)
This apparent “misconception” surrounding the vaccine's role in the
healing of ailments can be interpreted as a source of concern for the
ethical conduct of a clinical trial, and as casting doubt over the in-
formed consent process. However, as discussed below, we might instead
consider the importance of diﬀerentiating formal informed consent
processes from hope, especially in contexts characterised by great un-
certainty.
Overall, these diﬀering ideas of opportunity, perceived beneﬁt and
even the imputation of healing powers, to the perceptions of vaccine
risks and beneﬁts, and reﬂect the hope characterising participants'
descriptions of their motivations for joining.
4.4. Expectations and notions of exchange
A ﬁnal, often-cited reason for joining the trial was a diﬀerent kind of
perceived opportunity, expressed in terms of expectations about what
might happen once the vaccine trial was over. These expectations were
deeply rooted in notions of reciprocity, which suggested that one could
reasonably expect altruistic behaviour or bravery to be rewarded in the
future:
We went, and we said: ‘If we die, we will die’, so what is [there] for
us? What is the beneﬁt? (Female Participants Focus Group
12.05.2016)
This may appear to counter the notions of pure volunteerism that
appear to be embodied by the altruistic motivations described above.
However, as anthropological theories of gift-giving have long high-
lighted, altruism must be deﬁned in relational terms that collapse the
“liberal notion of autonomous choice” (Geissler, 2011, p. 47). Instead,
these theories point to the norms of reciprocity that emerge from new
collectivities, such as the trial community that participants entered. In
this sense, expectations or hopes regarding what might happen once
they had entered the trial, with full knowledge that these beneﬁts had
not been promised, are in line with expressions of altruism and sacri-
ﬁce.
In some instances, especially at times when jobs were advertised by
the trial, some participants articulated an anticipation that being a
study participant might help them gain employment (even though the
trial protocol forbids hiring participants). The arrival of the trial was
often described as evidence of “development”, a source of various op-
portunities including increased demand for housing and commodities.
Employment was one such opportunity. Expectations of material re-
wards have to be placed in the context of Sierra Leone's political
economy and more speciﬁcally against the limited opportunities
available in Kambia, a largely rural district with a 60% poverty rate
(OCHA, 2015). Hopes that joining the trial might be rewarded with
future employment thus simply reﬂected broader strategies for acces-
sing opportunities through recognition and the creation of networks of
reciprocity in an overcrowded market where labour supply far out-
weighs demand (Enria, 2018, 2015). Signiﬁcantly, however, the most
widely shared expectation or wish was the rather modest one that
participants might be given certiﬁcates at a public ceremony the end of
the process and thereby be recognised for their sacriﬁces. As Le Marcis
(2012, p.488) argues, building on Honnerth's (2008) work, struggles for
recognition are central to the “self-realization of the individual”, and
can thus be seen as the deepest and most fundamental motivations for
human behaviour.
5. Discussion
The motivations that participants reported for joining the trial raise
interesting questions that can contribute to on-going debates on how
clinical trial ethics can be grounded in local realities. This is especially
the case in the context of an epidemic whose social dimensions had
signiﬁcant implications for social perceptions of the risks posed by new
biomedical interventions. By contributing novel empirical data from the
West African Ebola outbreak, this paper speaks directly to the speciﬁc
concerns of community engagement for medical research in outbreak
and post-outbreak settings. The context of the Ebola outbreak allows us
to ﬂip the question driving research on vaccine hesitancy to ask why
people decided to take the EBOVAC-Salone vaccine candidate given
multiple levels of uncertainty, including that relating to medical re-
search and deeper contextual mistrust arising from both historic and
contemporary factors. Focusing on motivation for participating and
how these emerge from social constructions of risk in an emergency
context raises important questions about the nature of informed consent
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and incentives for joining medical research.
Participant motivations to join show how rumours and mistrust that
emerged during the epidemic inﬂuenced the landscape facing re-
searchers. These concerns, even when participants dismissed them,
informed their estimations of the level of risk they faced. At the same
time, participants' self-reported motivations for joining reveal their ef-
forts to create alternative, socially shared narratives based on hope,
optimism and a sense of commitment to one's community. Community
engagement teams and trialists cannot predict the acceptability of
clinical research. However, they can take social acceptability seriously
by engaging with rumours as social commentary, understanding how
they shape fears but also how they are challenged through the creation
of alternative narratives.
Studying subjective experiences reveals how narratives about sci-
ence and speciﬁc research projects shape perceptions of both risks and
beneﬁts. This oﬀers important insights for understanding the determi-
nants of the acceptability of medical research. It suggests a grounded
ethics approach to ethical standards in resource-poor contexts. Taking
seriously fears and perceptions of risk alongside notions of hope, al-
truism, and expectations of exchange, helps us paint a more complex
picture of motivation and choice somewhere between pure vo-
lunteerism and the participant as paid labour. Discussions of the prac-
tical ethics of incentivising participants for joining a clinical trial in
low-income settings rarely take into account the intangible motivations
(e.g. status) that shape individual decisions for taking part.
As scholars of risk have long pointed out, individual and collective
evaluations of risk are inﬂuenced by a plethora of factors ranging from
trust in the source of information to the nature of the event being
evaluated and the distribution of risk in society (Abraham, 2009; Beck,
1992; Hobson-West, 2003; Larson et al., 2012). The experiences of
EBOVAC-Salone participants similarly show how perceptions of risk in
clinical research are rooted in speciﬁc social realities that extend far
beyond the pages of informed consent forms, into households and
communities where the value of the study is debated and vernacular-
ized. Ideas about what is risky or beneﬁcial are socially negotiated and
contested, drawing on symbolic and material resources outside the re-
search encounter. Contextualising rumours and anxieties around med-
ical research also entails grasping the way in which these shape in-
dividual motivations, which remain socially situated even as
individuals enter the clinic. This is also true for perceptions of beneﬁts:
while it may be unsurprising that quality healthcare and potential
protection from the virus are incentives to join, what do we make of
expectations, hopes or even seemingly unfounded beliefs about special
healing powers and hopes about employment?
In contexts like Sierra Leone, characterised by acute crisis and
widespread poverty, hope becomes a necessary resource, a means of
imagining the future that is not necessarily tied to current realities but
ﬁrmly reliant on leaps of faith. A grounded ethics approach would
therefore need to take these emotional and belief-driven factors into
account and consider how value is socially created at both the in-
dividual and collective level. The challenge in practice becomes how to
integrate hopes, dreams and fears in our understanding of informed
consent and of what ethics might mean in diﬀerent contexts. Whilst
keeping in mind the diﬀerence between consent and hope, in-
corporating social perceptions of risk and beneﬁt can begin to advance
and enrich our conversation on the social values of research (see Rid
and Shah, 2017; Horng and Grady, 2010).
This emphasis on a grounded form of research ethics that considers
subjective assessments and local context also means contemplating how
clinical trial protocols and ethical standards might interact with the
realities of political economy in the places where they occur. The hope
that participants held regarding employment by the trial might seem
entirely misplaced in a resource rich context, but in Sierra Leone where
the formal wage employment rate is below 10% and where employment
is seen as being gained through recognition and reciprocity, this takes
on a diﬀerent meaning.
We would argue, in agreement with Scheper-Hughes (2003), that
acknowledging the relevance of diﬀerent ways of knowing the world
and understanding self and others, need not amount to a suspension of
‘the ethical’. Ethnographic research can help us understand the com-
plexities of participation in clinical trials across diﬀerent socio-cultural
settings to better understand how context shapes decision-making.
Understanding these dynamics can help make clinical trial protocols
and ethical guidelines more socially relevant, ensuring that the funda-
mental principles that underpin research ethics are reﬂected in practice.
Furthermore, emphasising context must also mean taking into account
the implications of global hierarchies of power and the ways in which
external interventions can reproduce inequality and injustice (for ex-
ample providing healthcare only to healthy participants).
Recognising the global and local context can help us reconsider
notions of fairness and volunteerism. For example, if we recognise that
in a given context, decision-making does not happen at the individual
level and that it often happens outside the clinic, informed consent
processes can take this into account, through group informed consent
processes to complement individual sessions. Involving communities in
the design of clinical trial protocols from the very beginning can further
contribute to a grounded approach to clinical trial ethics.
A grounded ethics approach need not be enacted solely through
clinical trial protocols. Indeed, it may often be inappropriate for clinical
practices to be moulded by subjective experiences and socio-cultural
speciﬁcities. An example is the hope that participants expressed in the
vaccine's healing powers, where participants argued that inoculation
had cured them from a range of diseases, against clinical evidence. It
would be clearly inappropriate to suggest that protocols ought to in-
corporate these perceptions. Community engagement for medical re-
search, on the other hand, can exist in these liminal spaces between
clinical trial protocols and communities' shared meanings. Community
mobilisers are better placed than clinicians to think about whether and
how to engage with subjective assessments of beneﬁts in their cam-
paigns. Notions of sacriﬁce, for example, were central to participants'
motivations and to their struggle for social recognition and self-rea-
lisation, but they were developed in dialogue with a broader social
context of fear and uncertainty rather than with the legalistic risk as-
sessment provided by the clinical protocol.
An appreciation of the social constructions of risk and the im-
portance of recognition for self-realization poses a complex but poten-
tially productive challenge for those interested in developing messaging
and engagement strategies that are responsive to local context.
6. Conclusion
Participant motivations for joining an Ebola vaccine trial in the
immediate aftermath of a highly fatal disease outbreak oﬀer important
lessons for ethics and community engagement for clinical trial research
across diﬀerent contexts. Building on existing work on research ethics
in developing country contexts, we have shown how experiences from
an epidemic response can contribute to an on-going conversation about
how to strengthen the context-sensitivity of guidelines and protocols in
practice.
Participants in the EBOVAC-Salone trial joined for a variety of
complex reasons, yet highlighting their articulations of motivations in
terms of altruism; curiosity and hope; health seeking; and notions of
exchange, underscores the situated nature of risk-beneﬁt calculations.
Studying motivations in a context as extreme as the West African Ebola
outbreak gives important insights into the kind of factors that inﬂuence
decision making in clinical research more broadly. More signiﬁcantly,
the reasons outlined by the EBOVAC-Salone participants emphasise the
need to consider what motivates individuals to take part in a clinical
trial, taking into account that these reasons are socially situated and
context-speciﬁc. In particular, research during and after the outbreak
revealed how perceptions of risk are inﬂuenced by social engagements
with the epidemic. This has important implications for how we think
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about research ethics across vastly diﬀerent settings and how we design
mechanisms for participant recruitment and messaging.
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